Stay updated on Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab in Metastatic NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAddition of Revision: v3.4.2 and deletion of notices about government funding lapse and prior Revision: v3.4.1. These updates are administrative in nature and do not modify study data or core page content.SummaryDifference0.5%

- Check21 days agoChange DetectedAdded a government funding status banner noting possible delays and open status, and updated the site version to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedAdded a Show glossary toggle and new footer items (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0); removed or altered the previous items/labels (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4).SummaryDifference0.2%

- Check42 days agoChange DetectedRevision metadata updated: v3.3.4 was added and v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded a Locations section with a California site and updated the page revision to v3.3.3; the prior California Locations listing was removed.SummaryDifference0.2%

- Check85 days agoChange DetectedUpdated: Study Protocol and Statistical Analysis Plan to revision v3.3.2, replacing v3.3.1. This is an administrative document revision and does not alter core trial details or reported results on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Metastatic NSCLC Clinical Trial page.